-
公开(公告)号：US20100004215A1
公开(公告)日：2010-01-07
申请号：US12109752
申请日：2008-04-25
IPC分类号： A61K31/56 , A61K31/407 , A61K31/519 , A61K31/46
CPC分类号： A61K45/06 , A61K31/407 , A61K31/46 , A61K31/519 , A61K31/56 , A61K2300/00
摘要： Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.
摘要翻译： 本文提供包含一种或多种IV型磷酸二酯酶抑制剂（“PDE-IV”）和至少一种其它活性成分如毒蕈碱受体拮抗剂（MRA），β2-激动剂，p38 MAP激酶抑制剂或皮质类固醇的药物组合物，以及 任选地一种或多种药学上可接受的赋形剂。 此外，提供了治疗自身免疫性，炎性或过敏性疾病或病症的方法。
-
公开(公告)号：US20090054382A1
公开(公告)日：2009-02-26
申请号：US12090798
申请日：2006-10-19
IPC分类号： A61K31/573 , A61K31/407 , A61K31/424
CPC分类号： A61K31/41
摘要： Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.
摘要翻译： 本文提供了包含一种或多种IV型磷酸二酯酶抑制剂（“PDE-IV”）和至少一种选自毒蕈碱受体拮抗剂（MRA），β2-激动剂，p38 MAP激酶抑制剂和皮质类固醇的其它活性成分的药物组合物，以及 任选地一种或多种药学上可接受的赋形剂和/或其它治疗剂。 此外，提供了治疗自身免疫性，炎性或过敏性疾病或病症的方法。
-
公开(公告)号：US20100144801A1
公开(公告)日：2010-06-10
申请号：US12443838
申请日：2007-10-02
申请人： Naresh Kumar , Jaskiran Kaur , Abhijit Ray , Suman Gupta , Shivani Malhotra , Rajkumar Shirumalla
发明人： Naresh Kumar , Jaskiran Kaur , Abhijit Ray , Suman Gupta , Shivani Malhotra , Rajkumar Shirumalla
IPC分类号： A61K31/44 , C07D213/55 , C07D233/54 , A61K31/4164 , A61P11/00 , A61P13/00 , A61P1/00 , A61P3/00
CPC分类号： C07D233/64 , C07D211/70 , C07D213/30
摘要： The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.
摘要翻译： 本发明一般涉及式I的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式（I）其中Het：是杂环基或杂芳基X：O，S或NR1，其它取代基如权利要求中所定义。
-
公开(公告)号：US20100056496A1
公开(公告)日：2010-03-04
申请号：US12439771
申请日：2007-09-04
申请人： Naresh Kumar , Kirandeep Kaur , Yogesh D. Shejul , Abhijit Ray , Suman Gupta , Shivani Malhotra , Rajkumar Shirumalla
发明人： Naresh Kumar , Kirandeep Kaur , Yogesh D. Shejul , Abhijit Ray , Suman Gupta , Shivani Malhotra , Rajkumar Shirumalla
IPC分类号： A61K31/55 , C07D223/14 , A61P1/00 , A61P11/00 , A61P3/00
CPC分类号： C07D221/24 , C07D209/12 , C07D209/14
摘要： The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is.
摘要翻译： 本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备本文所述化合物的方法，其药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式（I）或其药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，非对映体，多晶型物或N-氧化物，其中X为。
-
公开(公告)号：US20090137623A1
公开(公告)日：2009-05-28
申请号：US12158435
申请日：2007-01-02
申请人： Naresh Kumar , Ian Anthony Cliffe , Mohammad Salman , Venkata P. Palle , Kirandeep Kaur , Yogesh D. Shejul , Anita Chugh , Suman Gupta , Abhijit Ray , Shivani Malhotra , Raj Kumar Shirumalla
发明人： Naresh Kumar , Ian Anthony Cliffe , Mohammad Salman , Venkata P. Palle , Kirandeep Kaur , Yogesh D. Shejul , Anita Chugh , Suman Gupta , Abhijit Ray , Shivani Malhotra , Raj Kumar Shirumalla
IPC分类号： A61K31/439 , C07D487/08 , A61P1/00 , A61P3/10 , A61P3/04 , A61P11/06
CPC分类号： C07D209/52
摘要： The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.
摘要翻译： 本发明涉及可用于治疗各种疾病和病症（例如阿尔茨海默病，青光眼，精神病）的式（I）的毒蕈碱受体调节剂，具体地，7-氧代-2-氮杂双环[2.2.1]庚烷 特别是精神分裂症或精神分裂症状，躁狂症，疼痛，双相情感障碍，抑郁症，睡眠障碍，癫痫，胃肠动力障碍，尿失禁和认知增强。
-
公开(公告)号：US20100168197A1
公开(公告)日：2010-07-01
申请号：US12528987
申请日：2008-02-27
申请人： Naresh Kumar , Jaskiran Kaur , Shelly Aeron , Abhijit Ray , Suman Gupta , Shivani Malhotra , Raj Kumar Shirumalla
发明人： Naresh Kumar , Jaskiran Kaur , Shelly Aeron , Abhijit Ray , Suman Gupta , Shivani Malhotra , Raj Kumar Shirumalla
IPC分类号： A61K31/4164 , C07D233/54
CPC分类号： C07D235/08 , C07D233/54 , C07D409/06
摘要： This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
摘要翻译： 本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。
-
公开(公告)号：US20100222393A1
公开(公告)日：2010-09-02
申请号：US12159505
申请日：2006-12-21
申请人： Naresh Kumar , Jaskiran Kaur , Venkata P. Palle , Beenu Bhatt , Shelly Jindal , Anita Chugh , Suman Gupta , Abhijit Ray , Shivani Malhotra , Raj Kumar Shirumalla
发明人： Naresh Kumar , Jaskiran Kaur , Venkata P. Palle , Beenu Bhatt , Shelly Jindal , Anita Chugh , Suman Gupta , Abhijit Ray , Shivani Malhotra , Raj Kumar Shirumalla
IPC分类号： A61K31/4439 , C07D233/54 , A61K31/4164 , C07D401/02 , A61P11/00 , A61P13/00 , A61P1/00 , A61P3/04 , A61P3/10
CPC分类号： C07D233/54 , C07D233/14 , C07D233/56 , C07D233/64 , C07D401/12
摘要： Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.
摘要翻译： 式（I）的化合物，当G为-OH时，当G为-O时，表示单键; R 1和R 2独立地选自氢，烷基，烯基，炔基，芳烷基，环烷基，芳基，杂芳基，杂环基，杂环基烷基或杂芳基烷基; R3选自氢，羟基，烷氧基，烯氧基或炔氧基; X选自氧，-NH，-NR（其中R是烷基，烯基，烯基，炔基或芳基），硫或无原子; Het是杂环基或杂芳基; n是1至6的整数; 是毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，尿和4I胃肠系统的各种疾病，以及其它用途。
-
公开(公告)号：US20080319002A1
公开(公告)日：2008-12-25
申请号：US11570749
申请日：2004-06-16
IPC分类号： A61K31/4353 , C07D221/04 , A61P1/00 , A61P13/02 , A61P3/04 , A61P3/10 , A61P9/00
CPC分类号： C07D405/12 , C07D405/14
摘要： This present invention generally relates to xanthine derivatives as muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
摘要翻译： 本发明一般涉及作为毒蕈碱受体拮抗剂的黄嘌呤衍生物，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。
-
公开(公告)号：US20090012116A1
公开(公告)日：2009-01-08
申请号：US11995376
申请日：2006-07-11
申请人： Naresh Kumar , Kirandeep Kaur , Sandeep Sinha , Suman Gupta , Venkata P. Palle , Anita Chugh
发明人： Naresh Kumar , Kirandeep Kaur , Sandeep Sinha , Suman Gupta , Venkata P. Palle , Anita Chugh
IPC分类号： A61K31/44 , C07D453/02 , A61K31/40 , C07D487/08
CPC分类号： C07D209/52 , C07D405/12 , C07D409/12 , C07D471/08
摘要： Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described herein, and methods for treating diseases mediated through muscarinic receptors.
摘要翻译： 提供毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿或胃肠系统的各种疾病。 还提供了用于制备本文所述化合物的方法，包含本文所述化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。
-
10.发明授权公开(公告)号：US06423529B1
公开(公告)日：2002-07-23
申请号：US09178695
申请日：1998-10-26
IPC分类号： C12N100
CPC分类号： G01N33/56905 , Y02A50/55
摘要： This invention is relation to a composition useful for the early diagnosis of visceral leishmaniasis comprising trypsinised and commassie brilliant blue stained Leishmania promastigotes and a protein stabilising solute in the ratios ranging from 5 million: 0.0001 mg to 100 million: 1.00 mg.
摘要翻译： 本发明涉及一种可用于早期诊断内脏利什曼病的组合物，其中包括胰蛋白酶消化和平均亮蓝染色的利什曼原虫前鞭毛体和蛋白质稳定溶质，其比例范围为500万至0.0001毫克至1.00毫克。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.023 秒)